KLP Kapitalforvaltning AS Invests $509,000 in LivaNova PLC (NASDAQ:LIVN)

KLP Kapitalforvaltning AS purchased a new stake in LivaNova PLC (NASDAQ:LIVN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 11,000 shares of the company's stock, valued at approximately $509,000.

A number of other large investors also recently bought and sold shares of LIVN. Cerity Partners LLC acquired a new position in shares of LivaNova during the 3rd quarter worth approximately $573,000. FMR LLC lifted its holdings in LivaNova by 68.0% during the third quarter. FMR LLC now owns 31,466 shares of the company's stock valued at $1,653,000 after purchasing an additional 12,735 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of LivaNova by 92.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 122,740 shares of the company's stock valued at $6,449,000 after purchasing an additional 58,807 shares during the period. Captrust Financial Advisors purchased a new stake in shares of LivaNova during the third quarter worth about $217,000. Finally, Verition Fund Management LLC raised its position in shares of LivaNova by 47.4% during the 3rd quarter. Verition Fund Management LLC now owns 11,542 shares of the company's stock worth $606,000 after purchasing an additional 3,710 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

LIVN has been the topic of several research analyst reports. The Goldman Sachs Group lowered their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. Wolfe Research lowered LivaNova from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, February 26th. Stifel Nicolaus reduced their price objective on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. StockNews.com raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Tuesday, March 25th. Finally, Mizuho reduced their target price on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $61.17.

LivaNova Trading Down 4.4 %

NASDAQ:LIVN traded down $1.55 during trading hours on Tuesday, hitting $33.85. The company had a trading volume of 1,002,279 shares, compared to its average volume of 618,664. LivaNova PLC has a 1 year low of $33.41 and a 1 year high of $64.48. The company has a market cap of $1.84 billion, a P/E ratio of 80.60 and a beta of 0.90. The company has a 50-day moving average of $42.52 and a 200 day moving average of $47.76. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.